TKT Announces Date of Fourth Quarter 2001 Financial Results and Conference Call
CAMBRIDGE, Mass., Jan 28, 2002 /PRNewswire-FirstCall via COMTEX/ -- Transkaryotic Therapies, Inc. (Nasdaq: TKTX chart, msgs) will release fourth quarter and year-end 2001 financial results on Monday, February 11, 2002 after the close of U.S. financial markets. In connection with this announcement, TKT will host a conference call and live audio webcast on Monday, February 11, 2002 at 5:00 pm EST.
Participants may access the call by dialing 706-679-4323 and referencing the access code 2869326. The call will also be broadcast live over the Internet at www.tktx.com under the Investor Information section. Please dial in 5 to 10 minutes prior to the scheduled conference call time or log on to the website at least 15 minutes prior to the call in order to register, download, and install any necessary software.
The conference call will be archived on the Internet for approximately 48 hours for those who are unable to hear it live. A replay of the call will also be accessible by telephone after 7:00 pm EST Monday, February 11, 2002 through midnight EST on Wednesday, February 13, 2002. To replay the call, dial 706-645-9291 using access code 2869326.
Transkaryotic Therapies, Inc. (TKT) is a biopharmaceutical company dedicated to the development and commercialization of products based on its three proprietary development platforms: Niche Protein(R) products, Gene- Activated(R) proteins, and gene therapy. The Company's Niche Protein product platform is based on protein replacement for the treatment of rare genetic diseases, a group of disorders characterized by the absence of certain metabolic enzymes. TKT's gene activation technology is a proprietary approach to the large-scale production of therapeutic proteins, which does not require the cloning of genes and their subsequent insertion into non-human cell lines. The Company's gene therapy technology, known as Transkaryotic Therapy(TM), is focused on the commercialization of non-viral, ex vivo gene therapy products for the long-term treatment of chronic protein deficiency states.
Gene-Activated(R), Niche Protein(R), and TKT(R) are registered trademarks and Transkaryotic Therapy(TM) is a trademark of Transkaryotic Therapies, Inc.
Please visit our web site at www.tktx.com for additional information about Transkaryotic Therapies, Inc.
CONTACT:
Justine E. Koenigsberg
Director, Corporate Communications
(617) 349-0271
Source: Transkaryotic Therapies, Inc.
Contact:
Justine E. Koenigsberg, Director, Corporate Communications of
TKT, +1-617-349-0271
/Company News On-Call: prnewswire.com
/Photo: NewsCom: newscom.com
AP Archive: photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
URL: tktx.com |
